cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Geron Corporation
34 own
44 watching
Current Price
$2.15
$-0.02
(-0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,877.22M
52-Week High
52-Week High
3.84000
52-Week Low
52-Week Low
1.95000
Average Volume
Average Volume
4.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,877.22M
icon52-Week High3.84000
icon52-Week Low1.95000
iconAverage Volume4.12M
iconDividend Yield--
iconP/E Ratio--
What does the Geron Corporation do?
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Read More
How much money does Geron Corporation make?
News & Events about Geron Corporation.
Business Wire
2 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Companys first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies, companies...
Zolmax
3 months ago
Geron (NASDAQ:GERN Get Rating) and Theseus Pharmaceuticals (NASDAQ:THRX Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, ...
Business Wire
3 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to...
Business Wire
3 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Companys first-in-class telomerase inhibitor, in patients with acute myeloid...
Business Wire
3 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence (TI), evidence for disease-modifying activity and favorable fatigue patient-reported outcomes (PRO) in...
Frequently Asked Questions
Frequently Asked Questions
What is Geron Corporation share price today?
plus_minus_icon
Can Indians buy Geron Corporation shares?
plus_minus_icon
How can I buy Geron Corporation shares from India?
plus_minus_icon
Can Fractional shares of Geron Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Geron Corporation stocks?
plus_minus_icon
What is today’s traded volume of Geron Corporation?
plus_minus_icon
What is today’s market capitalisation of Geron Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Geron Corporation?
plus_minus_icon
What percentage is Geron Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Geron Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$2.15
$-0.02
(-0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$73.48
$-1.25 (-1.67 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$12.88
$-0.43 (-3.23 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.78
$0.01 (1.89 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$95.06
$-0.38 (-0.40 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$73.48
$-1.25 (-1.67 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$12.88
$-0.43 (-3.23 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.78
$0.01 (1.89 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$95.06
$-0.38 (-0.40 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00